Inside EMA

From idea to medicines: how EMA supports innovation

How does EMA help turn innovative ideas into real medicines? In this episode of Inside EMA, we look at how the European Medicines Agency supports developers from early concepts through to patient access. The discussion highlights how regulation and innovation are not opposites, but complementary forces that help deliver safe and effective medicines. Topics include early scientific dialogue, support for SMEs, and EMA’s engagement with innovation ecosystems across Europe. 🎙️ Featuring Emmanuel Cormier, Head of regulatoryscience and innovation, and Alessandro Faia, Communications officer. Learn more: Opportunities to interact with EMA during the development of a medicine [https://www.ema.europa.eu/en/human-regulatory-overview/research-development#opportunities-to-interact-with-ema-during-the-development-of-a-medicine-38736]

Beyond the scale, obesity in the age of GLP-1s

Obesity rates continue to rise across Europe, but the reasons go far beyond diet and exercise. In this episode, we explore obesity as a chronic disease and look at how weight‑loss medicines like GLP‑1 receptor agonists are influencing treatment and expectations. EMA expert Bart van der Schueren joins us to discuss the biological, behavioural and societal factors that influence weight, and what it means to try to lose weight today.

Inoculated with doubt: misinformation and public trust

This episode of ‘Inside EMA’ delves into one of today’s most pressing public health challenges: health misinformation. Konstantina Boumaki, from the European Patients’ Forum EPF), and Steffen Thirstrup, EMA’s Chief Medical Officer, address the rise of health misinformation, the drivers of trust, especially among young people, and the actions EMA is taking to strengthen confidence in medicines and science.

Shortages of medicines: a balancing act

Medicine shortages are a growing challenge in today’s complex global supply chain. In this episode of Inside EMA, Monica Dias, EMA’s Head of Supply and Availability of Medicines and Medical Devices, joins communications officers Alessandro Faia and Giulia Gabrielli to explain how the Agency works, together with national authorities, to prevent and manage shortages across the EU. They also discuss the communication campaign Fighting medicine shortages: it takes a team [https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/medicine-shortages-availability-issues/fighting-medicine-shortages-it-takes-team] and why public awareness and strong collaboration with stakeholders are essential.

The next pandemic: are we ready?

When it comes to the next pandemic, the question is likely not to be about if it might happen, but rather when. In this episode, Marco Cavaleri, EMA’s Head of Public Health Threats, discusses with communications officer Sophie Labbe the Agency’s and his personal experience of the COVID-19 pandemic, the reasons why new pandemics are likely to occur, and how EMA is preparing for it.